What is MS Phase 3 Study DECIDE?
CATEGORY:
DECIDE is a Phase III, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis.
Save up to 80% off your prescriptions!
We currently don't have enough shared data that is made public for this treatment.
Let's build this page together! When you share what it's like to have MS Phase 3 Study DECIDE through your profile, those stories and data appear here too.
Last updated: